Basic Information
| LncRNA/CircRNA Name | circVANGL1 |
| Synonyms | |
| Region | |
| Ensemble | |
| Refseq |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qRT-PCR , western blot , Dual luciferase reporter assay , MTT assay , cell apoptosis analysis , transwell assay |
| Sample | NSCLC tissues and the matched adjacent normal tissues ,NSCLC cell lines (A549, H1299, H1975, SPC-A1 and SK-MES-1) and normal human bronchial epithelial cell line (16HBE) |
| Expression Pattern | up-regulated |
| Function Description | The results showed that circVANGL1 was overexpressed in human NSCLC tissues and cell lines. circVANGL1 expression was closely associated with tumor size, TNM stage and overall survival of NSCLC patients. Further loss-of-function analysis revealed that knockdown of circVANGL1 inhibited proliferation and induced apoptosis in NSCLC cell lines. The migration and invasion of NSCLC cells were also suppressed by circVANGL1 knockdown. In addition, we predicted that circVANGL1 might serve as a competing endogenous RNA (ceRNA), becoming a sink for miR-195, thereby modulating the expression of Bcl-2 in NSCLC cells. Rescue experiments demonstrated that miR-195 inhibitor abrogated the beneficial role of circVANGL1 knockdown in NSCLC cells. |
| Pubmed ID | 31076544 |
| Year | 2019 |
| Title | Up-regulated Circular RNA VANGL1 Contributes to Progression of Non-Small Cell Lung Cancer Through Inhibition of miR-195 and Activation of Bcl-2 |
External Links
| Links for circVANGL1 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |